Abstract: Techniques are disclosed relating to monitoring network traffic of an embeddable browser displayed by an application executing on a mobile computing device. In some embodiments, a first layer of the application manipulates one or more user interface elements displayed in the embeddable browser. The first layer of the application then detects network requests made by one or more application programming interfaces (APIs) executed by the embeddable browser in response to the manipulating. In some embodiments, the first layer sends to a second layer of the application results of observing network requests. In some embodiments, the second layer of the application displays, in real-time, information corresponding to the results of observing network requests.

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds of Formula (I) to pharmaceutical compositions comprising compounds of Formula (I) and to methods of use thereof, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions comprising those compounds.

Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds of Formula (I) to pharmaceutical compositions comprising compounds of Formula (I) and to methods of use thereof, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions comprising those compounds.

Abstract: Techniques are disclosed relating to monitoring network traffic of an embeddable browser displayed by an application executing on a mobile computing device. In some embodiments, a first layer of the application manipulates one or more user interface elements displayed in the embeddable browser. The first layer of the application then detects network requests made by one or more application programming interfaces (APIs) executed by the embeddable browser in response to the manipulating. In some embodiments, the first layer sends to a second layer of the application results of observing network requests. In some embodiments, the second layer of the application displays, in real-time, information corresponding to the results of observing network requests.

Abstract: Compounds that inhibit KRas G12D; in particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.

Abstract: A monitoring system and method determine a consumption metric representative of one or more of an amount of fuel consumed or an amount of energy consumed by a vehicle during travel over a route. The consumption metric is independent of one or more of vehicle load or elevation change over the route. The system and method optionally can determine a route condition metric representative of a condition of a route traveled upon by a vehicle. The route condition metric is based on a comparison between an actual grade of the route at one or more locations along the route and an estimated grade of the route at the one or more locations.

Abstract: Described are systems and techniques configured to provide a user interface for an unauthenticated user of a materials handling facility. A transient profile indicative of one or more user preferences may be created and associated with the unauthenticated user. As the unauthenticated user interacts with the facility, preferences may be determined and included in the transient profile. Subsequent operation of the facility may take into account the transient profile. As the unauthenticated user moves throughout the facility, the transient profile may “follow” them, providing an ongoing user experience. Should the unauthenticated user later be authenticated, the transient preferences may be incorporated into a persistent profile.

Abstract: Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Abstract: A monitoring system and method determine a consumption metric representative of one or more of an amount of fuel consumed or an amount of energy consumed by a vehicle during travel over a route. The consumption metric is independent of one or more of vehicle load or elevation change over the route. The system and method optionally can determine a route condition metric representative of a condition of a route traveled upon by a vehicle. The route condition metric is based on a comparison between an actual grade of the route at one or more locations along the route and an estimated grade of the route at the one or more locations.

Abstract: Functionality of sensors on a shelf or other inventory location is tested by encouraging an interaction and determining if the output from the sensors on the shelf is consistent with the interaction. An interaction at the shelf can include, for example, a user adding or removing an item from the shelf. To encourage this type of interaction with the shelf or items therein, an announcement may be generated and presented to a user. The announcement may comprise an advertisement with some type of incentive for the user to add or remove an item from the shelf. Upon verifying such an interaction, sensor data before and after the interaction can be compared to generate diagnostic data for the sensor, which can indicate whether the sensor is operational or malfunctioning.

Abstract: The present disclosure relates to compounds of Formula (I), or pharmaceutically, acceptable salts thereof, that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present disclosure relates to compounds, or pharmaceutically acceptable salts thereof pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising compounds of Formula (I), or pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions of the present invention.

Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Abstract: Embodiments of the subject matter disclosed herein relate to controlling engine operating points and power for full throttle command in an off-highway vehicle, such as a diesel electric haul truck, to increase fuel efficiency. In one example, a system includes an engine and a controller. The controller is configured to determine a target engine horsepower and associated target engine speed, command the engine to operate at a first engine speed above the target engine speed, adjust a load placed on the engine to reach the target engine speed, and command the engine to operate at a second engine speed to reach the target engine horsepower.

Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.